Keros Therapeutics (KROS) Competitors $13.33 -0.08 (-0.60%) As of 07/3/2025 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. ARWR, VCEL, DNLI, RXRX, NAMS, KNSA, APGE, CGON, BLTE, and IDYAShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), CG Oncology (CGON), Belite Bio (BLTE), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Arrowhead Pharmaceuticals Vericel Denali Therapeutics Recursion Pharmaceuticals NewAmsterdam Pharma Kiniksa Pharmaceuticals International Apogee Therapeutics CG Oncology Belite Bio IDEAYA Biosciences Keros Therapeutics (NASDAQ:KROS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has more risk and volatility, KROS or ARWR? Keros Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Do analysts rate KROS or ARWR? Keros Therapeutics currently has a consensus price target of $30.56, suggesting a potential upside of 129.22%. Arrowhead Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 160.51%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has higher earnings & valuation, KROS or ARWR? Keros Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Keros Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M152.53-$187.35M-$0.18-74.06Arrowhead Pharmaceuticals$545.21M4.25-$599.49M-$1.40-11.99 Is KROS or ARWR more profitable? Keros Therapeutics has a net margin of 1.96% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Keros Therapeutics' return on equity of 0.75% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics1.96% 0.75% 0.69% Arrowhead Pharmaceuticals N/A -45.33%-12.49% Do insiders & institutionals believe in KROS or ARWR? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to KROS or ARWR? In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 1 mentions for Arrowhead Pharmaceuticals and 0 mentions for Keros Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.54 beat Keros Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Keros Therapeutics Neutral Arrowhead Pharmaceuticals Very Positive SummaryKeros Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$541.47M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-74.0621.5627.4720.28Price / Sales152.53244.81408.86121.46Price / CashN/A41.9536.6357.47Price / Book0.947.518.095.68Net Income-$187.35M-$55.05M$3.17B$248.96M7 Day Performance-1.19%4.61%2.81%3.30%1 Month Performance-10.05%4.89%3.67%5.20%1 Year Performance-68.39%5.84%35.41%21.37% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.6387 of 5 stars$13.33-0.6%$30.56+129.2%-68.4%$541.47M$3.55M-74.06100ARWRArrowhead Pharmaceuticals3.9375 of 5 stars$15.62-0.3%$43.71+179.9%-33.1%$2.15B$3.55M-11.13400VCELVericel2.946 of 5 stars$41.77-0.3%$61.14+46.4%-7.0%$2.10B$238.54M1,392.96300Positive NewsDNLIDenali Therapeutics4.535 of 5 stars$14.43-0.2%$33.71+133.7%-31.0%$2.09B$330.53M-5.39430RXRXRecursion Pharmaceuticals2.1244 of 5 stars$5.12-0.9%$7.00+36.9%-28.4%$2.07B$58.84M-2.87400Analyst ForecastNAMSNewAmsterdam Pharma3.0736 of 5 stars$18.54+1.1%$42.89+131.3%-0.8%$2.06B$45.56M-9.764KNSAKiniksa Pharmaceuticals International3.6932 of 5 stars$28.02-1.3%$38.80+38.5%+45.8%$2.04B$423.24M-112.06220Positive NewsAPGEApogee Therapeutics2.9022 of 5 stars$43.08+0.2%$94.60+119.6%+26.8%$1.98BN/A-11.9691News CoverageAnalyst ForecastInsider TradeCGONCG Oncology2.4142 of 5 stars$25.99-0.3%$58.67+125.8%-12.8%$1.98B$1.14M-17.1861BLTEBelite Bio2.5064 of 5 stars$61.00-0.2%$96.67+58.5%+30.6%$1.94BN/A-44.8510Analyst ForecastGap UpIDYAIDEAYA Biosciences3.5496 of 5 stars$22.09+0.4%$53.42+141.8%-33.6%$1.93B$7M-6.1480 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Alternatives Vericel Alternatives Denali Therapeutics Alternatives Recursion Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Kiniksa Pharmaceuticals International Alternatives Apogee Therapeutics Alternatives CG Oncology Alternatives Belite Bio Alternatives IDEAYA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts